Table 9.
Approved cannabis-based drugs by a national regulatory authority for clinical use and related patent data
| Drug proprietary name | Active pharmaceutical ingredient | Medical condition | Company | Country and year of approval | Relevant patents and dates of expiry |
|---|---|---|---|---|---|
| Cesamet | Nabilone (synthetic cannabinoid) | Nausea, Multiple sclerosis, Fibromyalgia | Eli Lilly, Valeant | USA, 1985,2006, UK, EU Austria, Belgium, Spain, variously from 2007 |
US4195078—expired 1999 EP2004075590—expired 2018 |
| Epidiolex | Cannabidiol (CBD) | Epilepsy | GW Pharma |
USA 2018 EU 2019 |
US10/468041—expiry date 2026 US9956185—expiry date 2035 US9066920—expiry date 2032 |
| Marinol | Dronabinol (synthetic Tetrahydrocannabinol (THC) | HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting | Solvay Pharmaceuticals | USA 1985, 1992 |
US5166145—expired 2010 US6383513—expired 2018 |
| Sativex | THC and CBD in a 1:1 ratio | neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis | GW Pharma | UK 2010 and various European countries, Canada 2005 |
US20060135599A1—expiry date 2022 US10538373—estimated expiry date 2022 |
| Syndros | Synthetic THC (Dronabinol) in liquid formulation for oral administration | Nausea and vomiting caused by chemotherapy, loss of appetite | Insys Therapeutics | US 2016 |
US9345771—expiry date 2028 US8222292—expiry date 2028 |